Isolation and characterization of DNA from the plasma of cancer patients

Stroun, Maurice; Anker, Philippe; Lyautey, Jacqueline; Lederrey, Christine; Maurice, P

doi:10.1016/0277-5379(87)90266-5

Cited by 313 publications

(208 citation statements)

References 8 publications

Supporting

Mentioning

193

Contrasting

Unclassified

Order By: Relevance

“…It is widely known that a substantial, if not predominant (depending on the course of therapy) portion of plasma DNA in cancer patients derives from tumor cells [27]. Higher plasma concentrations have been described in patients with large tumors or at an advanced stage of the disease [2,3,9,28,29] and it has been postulated that circulating plasma DNA in these disease states originates largely from tumor lysis/ m Male, f female, good less than 1,000 leukemic blood blasts on treatment day 8, poor more than 1,000 leukemic blood blasts, SR negative at days 33 and 78, HR still 10 −3 or more at day 78, MR all others, TEL/AML1 fusion transcript positivity, none of the patients was positive for the BCR/ ABL fusion transcript or an MLL aberration necrosis and apoptosis. In 2001, Jahr et al described a significant increase of plasma DNA after induction of apoptosis and necrosis in both, a cell culture and a murine model system, with the increase being more impressive in the necrosis model [30].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Quantification of free total plasma DNA and minimal residual disease detection in the plasma of children with acute lymphoblastic leukemia

et al. 2009

Self Cite

View full text Add to dashboard Cite

The analysis of total plasma DNA and the monitoring of leukemic clone-specific immunoglobulin and/or T-cell receptor gene rearrangements for the evaluation of minimal residual disease (MRD) in the plasma may be useful tools for prognostic purposes or for early detection of subclinical disease recurrence in children with acute lymphoblastic leukemia (ALL). The aim of this paper is to establish reference ranges for total plasma DNA concentrations and to test the feasibility of MRD measurements employing plasma DNA from children with ALL by using real-time quantitative (RQ)-PCR. Despite wide interindividual variation, the median concentrations of total plasma DNA for 12 healthy donors (57 ng/ml), 21 children with ALL after day 4 of treatment initiation (62 ng/ml) and 13 children with other malignancies (76 ng/ml) were similar. However, ALL patients had significantly higher concentrations at diagnosis (277 ng/ml) and on treatment day 3 (248 ng/ml) before returning to normal afterwards. Early plasma DNA MRD kinetics could be established for 15 ALL patients and showed good concordance with bone marrow MRD. Plasma DNA was higher in children with ALL at diagnosis but returned to normal within the first four treatment days. Despite low concentrations of DNA, it is feasible to measure MRD kinetics in plasma DNA during ALL induction therapy by adapted real-time PCR methodologies.

show abstract

Section: Discussionmentioning

confidence: 99%

“…In this context, various malignancies have been associated with increased concentrations of free plasma DNA as compared to levels in healthy controls [1][2][3]. It has therefore been proposed that analyses of free plasma DNA could be a useful tool for prognosis or the early diagnosis to detect subclinical disease recurrence [4].…”

Section: Introductionmentioning

confidence: 99%

Quantification of free total plasma DNA and minimal residual disease detection in the plasma of children with acute lymphoblastic leukemia

et al. 2009

Self Cite

View full text Add to dashboard Cite

show abstract

“…The physiological role of sFasL is controversial since it has been reported to induce non-apoptotic signals, possibly including NF-kβ-mediated stimulation of cell proliferation, survival or inflammation within an elevated cytokine milieu (Suda, et al 1997, Mogi, et al 2001, Serrao, et al 2001). In addition to FasL, circulating cell free DNA (cfDNA) has quite recently been discovered as a potential marker of inflammation, apoptosis, senescence and malignant conditions (Stroun, et al 1987, Fatouros, et al 2006, Jylhava, et al 2012). …”

Section: Introductionmentioning

confidence: 99%

Circulating miR-21, miR-146a and Fas ligand respond to postmenopausal estrogen-based hormone replacement therapy – A study with monozygotic twin pairs

Kangas

Pöllänen

Rippo

et al. 2014

Mechanisms of Ageing and Development

View full text Add to dashboard Cite

“…[15][16][17][18][19][20][21][22][23] Despite the use of similar PCR-based techniques, the published studies showed a broad range of detection rates of LOH with contradictory results in lung, colorectal and breast cancer patients. 19,20,[24][25][26] Increased concentrations of extracellular DNA have been detected in the plasma from numerous cancer patients 15,27 including PCa patients [28][29][30][31] compared with the low amounts detected in the blood from healthy individuals. The origin of free DNA in blood and BM is still discussed, and it is supposed that free extracellular DNA, which is early released into the blood circulation during the formation of primary tumors, is derived from necrotic and apoptotic cells.…”

mentioning

confidence: 99%

Detection of tumor‐specific DNA in blood and bone marrow plasma from patients with prostate cancer

Schwarzenbach

Chun

Lange

et al. 2007

Intl Journal of Cancer

View full text Add to dashboard Cite

Tumor tissues, blood plasma and bone marrow (BM) aspirates of 57 prostate cancer patients (PCa) without clinical signs of overt metastases were assessed for LOH (loss of heterozygosity) by a PCRbased fluorescence microsatellite analysis, using a panel of 15 markers. Additionally, micrometastatic tumor cells in BM were monitored by an immunocytological cytokeratin assay. In total, 25 (44%), 32 (56%) and 41 (72%) of the patients had at least 1 LOH in their blood, BM and tumor samples, respectively. Among the informative cases, the frequency of LOH was highest in blood plasma for the markers D8S360 (18%) and D10S1765 (15%), and in BM plasma for THRB (24%) and D8S137 (22%). Comparison of blood plasma and BM with tumors showed discrepant results in 35% and 45% of patients, respectively. Whereas all LOHs at THRB in BM plasma were also detected in the autologous tumor tissues, LOHs at D6S474 and D11S898 in BM were not retrieved in the tumors. The comparison with established risk factors showed a correlation of borderline significance for LOH at D9S1748 in the BM aspirates (p 5 0.055) and a significant correlation in the tumor samples (p 5 0.004) with increasing pathologic Gleason scores. Interestingly, 22% of the PCa patients harbored tumor cells in their BM and tended (p 5 0.065) to have more frequent LOH (16%) in BM plasma compared to patients without tumor cells (9%). These data demonstrate, for the first time, the presence of free tumor-specific DNA in blood and BM of PCa patients and suggest a possible relationship to BM micrometastasis. ' 2007 Wiley-Liss, Inc.

show abstract

Isolation and characterization of DNA from the plasma of cancer patients

Cited by 313 publications

References 8 publications

Quantification of free total plasma DNA and minimal residual disease detection in the plasma of children with acute lymphoblastic leukemia

Quantification of free total plasma DNA and minimal residual disease detection in the plasma of children with acute lymphoblastic leukemia

Circulating miR-21, miR-146a and Fas ligand respond to postmenopausal estrogen-based hormone replacement therapy – A study with monozygotic twin pairs

Detection of tumor‐specific DNA in blood and bone marrow plasma from patients with prostate cancer

Contact Info

Product

Resources

About